Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 2/20 | 0.38 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9857324 | 1.00 | HPGD (0.43) | HPGDTSHRKAT2BLMNAALDH1A1 | |
| SCHEMBL9623592 | 1.00 | HPGD (0.43) | HPGDTSHRKAT2BLMNAALDH1A1 | |
| SCHEMBL11701038 | 1.00 | HPGD (0.43) | HPGDTSHRKAT2BLMNAALDH1A1 | |
| SCHEMBL11762132 | 0.98 | TSHR (0.42) | HPGDTSHRKAT2BLMNAALDH1A1 | |
| SCHEMBL11764316 | 0.94 | TSHR (0.44) | HPGDTSHRKAT2BLMNAALDH1A1 | |
| SCHEMBL9623083 | 0.91 | GSTP1 (0.45) | HPGDTSHRKAT2BLMNAALDH1A1 | |
| SCHEMBL9623169 | 0.91 | GSTP1 (0.45) | HPGDTSHRKAT2BLMNAALDH1A1 | |
| SCHEMBL11698888 | 0.87 | GSTP1 (0.40) | HPGDTSHRKAT2BLMNAALDH1A1 | |
| SCHEMBL10684040 | 0.85 | CYP4F2 (0.46) | TSHRALDH1A1KMT2AGSTP1GAA | |
| SCHEMBL11106157 | 0.85 | CYP4F2 (0.46) | TSHRALDH1A1KMT2AGSTP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4142056-A | MULTISTAGE PROCESS FOR PREPARING 2-(6'-CARBOMETHOXYHEXYL)-2-CYCLOPENTEN-1-ONE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1979-02-27 | — | — | US | claimed |
| CN-108929225-B | Methyl pelargonate separating and purifying method | 浙江工业大学 | 2021-06-08 | — | — | CN | disclosed |
| US-10759734-B2 | Process for the preparation and purification of misoprostol | CHINOIN PHARMACEUTICAL AND CHEMICAL WORKS PRIVATE COMPANY LTD. (HU) | 2020-09-01 | — | — | US | disclosed |
| US-20200165186-A1 | PROCESS FOR THE PREPARATION AND PURIFICATION OF MISOPROSTOL | CHINOIN PHARMACEUTICAL AND CHEMICAL WORKS PRIVATE CO. LTD. (HU) | 2020-05-28 | — | — | US | disclosed |
| EP-2188380-B1 | Method for the coproduction of methyl 7-oxoheptanoate and undecylenic acid from ricinoleic acid | ARKEMA FRANCE (FR) | 2011-05-11 | — | — | EP | disclosed |
| US-20100203600-A1 | METHOD FOR THE COPRODUCTION OF METHYL 7-OXOHEPTANOATE AND UNDECYLENIC ACID FROM RICINOLEIC ACID | ARKEMA FRANCE (FR) | 2010-08-12 | — | — | US | disclosed |
| EP-2188380-A2 | METHOD FOR THE COPRODUCTION OF METHYL 7-OXOHEPTANOATE AND UNDECYLENIC ACID FROM RICINOLEIC ACID | ARKEMA FRANCE (FR) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009047446-A2 | METHOD FOR THE COPRODUCTION OF METHYL 7-OXOHEPTANOATE AND UNDECYLENIC ACID FROM RICINOLEIC ACID | ARKEMA FRANCE (FR) | 2009-04-16 | — | — | WO | disclosed |
| EP-1716113-B1 | EP2- RECEPTOR AGONISTS | ASTERAND UK LTD (GB) | 2009-02-25 | — | — | EP | disclosed |
| EP-1716113-B1 | EP2- RECEPTOR AGONISTS | ASTERAND UK LTD (GB) | 2009-02-25 | — | — | EP | disclosed |
| US-4039563-A | Process for preparing cyclopent-2-en-1-one derivatives | TEIJIN LIMITED (JA) | 1977-08-02 | — | — | US | disclosed |
| US-4031129-A | LITHIUM CYCLOPENTADIENE, ETHYL-7-BROMOHEPTANOATE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1977-06-21 | — | — | US | disclosed |
| US-4029698-A | Cycloalkylidenol analogues of prostaglandins E and F | MILES LABORATORIES, INC. (US) | 1977-06-14 | — | — | US | disclosed |
| US-4018811-A | MICROBIOCIDES, ANTIULCER, HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
| US-4007210-A | PROSTANOIC ACID DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 1977-02-08 | — | — | US | disclosed |
| US-4004027-A | Prostaglandin antagonists | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-01-18 | — | — | US | disclosed |
| US-3993674-A | ANTIULCER, BRONCHODILATOR, HYPOTENSIVE | AMERICAN CYANAMID COMPANY (US) | 1976-11-23 | — | — | US | disclosed |
| US-3970683-A | 11,15-Dihydroxy-9-oxoprost-13-ynoic acid | G. D. SEARLE & CO. (US) | 1976-07-20 | — | — | US | disclosed |
| US-3966773-A | BRONCHODILATOR, HYPOTENSIVE, ANTIULCER | AMERICAN CYANAMID COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3932479-A | BRONCHODILATOR, HYPOTENSIVE, ANTIULCER | AMERICAN CYANAMID COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759734-B2 | Process for the preparation and purification of misoprostol | F12, VKORC1L1, SART3 | HPGD 302/4885TSHR 773/4885KAT2B 1935/4885 |
| US-20200165186-A1 | PROCESS FOR THE PREPARATION AND PURIFICATION OF MISOPROSTOL | SART3, TBL3, TMSB4X | HPGD 1488/4885TSHR 70/4885KAT2B 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.